¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"leukemia inhibitory factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® chronic lymphocytic leukemia ÇÑ±Û ¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´
¼³¸í   
  ¹éÇ÷º´(leukemia)¶õ ºñÁ¤»óÀûÀΠ¹éÇ÷±¸ ¼¼Æ÷ÀÇ Áõ½Ä¿¡ ÀÇÇØ ÀϾ´Â º´ÀûÀΠ»óŸ¦ ¸»Çϴµ¥, ÈçÈ÷ ¸»ÃÊÇ÷¾×¿¡ ¹ÌºÐÈ­¼¼Æ÷°¡ ³ªÅ¸³ª¸ç, Á¤»óÀûÀΠÀûÇ÷±¸¼¼Æ÷¿Í ¹éÇ÷±¸¼¼Æ÷, Ç÷¼ÒÆÇÀÇ ±Þ°ÝÇÑ °¨¼Ò¸¦ °¡Á®¿Í Á¤»óÀûÀΠ¼¼Æ÷¿¡ ÀÇÇØ ÇàÇØÁö´Â ¿©·¯ ±â´ÉÀÇ °¨¼Ò¸¦ ÁÖÁõ»óÀ¸·Î ÇÏ¿© º´¿ø¿¡ Ã£¾Æ¿À°Ô µÈ´Ù. µû¶ó¼­ ÀûÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ºóÇ÷, ¹éÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ¸¹Àº °¨¿°Áõ¼¼(ÈçÈ÷ °É¸®Áö ¾Ê´Â ¼¼±Õ¿¡ ÀÇÇÑ °¨¿°, Áö³ªÄ¡°Ô ÀæÀº °¨±â, Æó·Å µî), Ç÷¼ÒÆÇ¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ÃâÇ÷Áõ»óÀÌ ³ªÅ¸³­´Ù. ¶ÇÇÑ ÇǸ¦ »ý»êÇϴ °ñ¼ö Á¶Á÷¿¡¼­´Â ÀÌ·± ºñÁ¤»óÀûÀΠ¼¼Æ÷ÀÇ Áõ½Ä¸¸À» º¼ ¼ö ÀÖÀ¸¸ç, Á¤»óÀûÀΠ¼¼Æ÷ÀÇ Áõ½ÄÀº º¸±â Èûµé´Ù.
  
  ¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´Àº ¼­¾ç¿¡¼­´Â ºñ±³Àû ¹éÇ÷º´ Áß¿¡¼­ ÈçÇÑ ÇüÀÌÁö¸¸ µ¿¾ç±Ç¿¡¼­´Â ¾ÆÁÖ µå¹® ¹éÇ÷º´ÀÇ ÇüÅÂÀÌ´Ù. ´ë°³ 60¼¼ ÀÌ»óÀÇ °í·ÉÃþ¿¡¼­ ¸¹ÀÌ »ý±â°í 30¼¼ ÀÌÇÏ¿¡¼­´Â °ÅÀǠã¾Æº¼ ¼ö°¡ ¾ø´Ù. Ç÷¾×°Ë»ç»ó¿¡¼­ ¸²ÇÁ±¸ÀÇ ¸¹Àº Áõ°¡¸¦ º¼ ¼ö°¡ ÀÖ°í, ´ë½Å¿¡ ´Ù¸¥ Ç÷¾×¼¼Æ÷µéÀº °¨¼Ò¸¦ ³ªÅ¸³½´Ù. ¹éÇ÷º´ Áß ¿¹Èİ¡ ÁÁÀº ÆíÀ̸破밳 Ä¡·á´Â Ç×¾ÏÁ¦¸¦ ÀÌ¿ëÇÑ È­Çпä¹ýÀ» ¸¹ÀÌ »ç¿ëÇϸç, Æò±Õ »ýÁ¸±â°£Àº 4~5³âÀÌ´Ù.
¿µ¹® leukemia ÇÑ±Û ¹éÇ÷º´
¼³¸í   
  ºñÁ¤»óÀûÀΠ¹éÇ÷±¸ ¼¼Æ÷ÀÇ Áõ½Ä¿¡ ÀÇÇØ ÀϾ´Â º´ÀûÀΠ»óŸ¦ ¸»Çϴµ¥, ÈçÈ÷ ¸»ÃÊ Ç÷¾×¿¡ ¹ÌºÐÈ­¼¼Æ÷°¡ ³ªÅ¸³ª¸ç, Á¤»óÀûÀΠÀûÇ÷±¸¼¼Æ÷¿Í ¹éÇ÷±¸¼¼Æ÷, Ç÷¼ÒÆÇÀÇ ±Þ°ÝÇÑ °¨¼Ò¸¦ °¡Á®¿Í Á¤»óÀûÀΠ¼¼Æ÷¿¡ ÀÇÇØ ÇàÇØÁö´Â ¿©·¯ ±â´ÉÀÇ °¨¼Ò¸¦ ÁÖÁõ»óÀ¸·Î ÇÏ¿© º´¿ø¿¡ Ã£¾Æ¿À°Ô µÈ´Ù. µû¶ó¼­ ÀûÇ÷±¸ ¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ºóÇ÷, ¹éÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ¸¹Àº °¨¿°Áõ¼¼(ÈçÈ÷ °É¸®Áö ¾Ê´Â ¼¼±Õ¿¡ ÀÇÇÑ °¨¿°, Áö³ªÄ£ ÀæÀº °¨±â, Æó·Å µî), Ç÷¼ÒÆÇ¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ÃâÇ÷Áõ»óÀÌ ³ªÅ¸³­´Ù. ¶ÇÇÑ ÇǸ¦ »ý»êÇϴ °ñ¼ö Á¶Á÷¿¡¼­´Â ÀÌ·± ºñÁ¤»óÀûÀΠ¼¼Æ÷ÀÇ Áõ½Ä¸¸À» º¼ ¼ö ÀÖÀ¸¸ç, Á¤»óÀûÀΠ¼¼Æ÷ÀÇ Áõ½ÄÀº º¸±â Èûµé´Ù.
  
  ÀÌ·± ¹éÇ÷º´¿¡´Â ¿©·¯ °¡Áö°¡ Àִ µ¥ Å©°Ô 4°¡Áö·Î ³ª´©¾î ºÐ·ùÇÑ´Ù. Á¤»óÀûÀ¸·Î ¹éÇ÷±¸¼¼Æ÷´Â ¸²ÇÁ°è¼¼Æ÷¿Í °ñ¼ö°è¼¼Æ÷·Î 2ºÐµÇ´Âµ¥, ¹éÇ÷º´ ¶ÇÇÑ ÀÌ·± ¸²ÇÁ°è¼¼Æ÷ÀÇ Áõ½Ä°ú °ñ¼ö°è¼¼Æ÷ÀÇ Áõ½Ä¿¡ µû¶ó ³ª´©¸ç, ±× Áõ»óÀÌ ¾ó¸¶³ª »¡¸® ³ªÅ¸³ª´Â °¡¿¡ µû¶ó ¸¸¼º, ±Þ¼ºÀ¸·Î ³ª´«´Ù. µû¶ó¼­ ¿©±â¿¡´Â ´ÙÀ½ 4°¡ÁöÀÇ ºÐ·ù°¡ ³ª¿À°Ô µÈ´Ù.
  
  -±Þ¼º¸²ÇÁ¼º ¹éÇ÷º´: acute lymphocytic
  
  -±Þ¼º°ñ¼ö¼º ¹éÇ÷º´: acute myelogenous
  
  -¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´: chronic lymphocytic
  
  -¸¸¼º°ñ¼ö¼º ¹éÇ÷º´: chronic myelogenous.
¿µ¹® rheumatoid factor ÇÑ±Û ·ù¸¶Æ¼½º ÀÎÀÚ
¼³¸í   
  IgGÀÇ FcºÎÀ§¿¡ Àִ Ç׿ø°áÁ¤ÀÎÀÚ¿¡ ´ëÇÑ Ç×ü·Î¼­ ÀüÇüÀûÀΠ¶Ç´Â È®½ÇÇÑ ·ù¸¶Æ¼½º°üÀý¿°(rheumatoid arthritis) È¯ÀÚÀÇ 80%¿¡¼­ ¹ß°ßµÈ´Ù. ·ù¸¶Æ¼½º ÀÎÀڴ IgM, IgG, IgAÁß Çϳª°¡ µÉ ¼ö ÀÖÀ¸³ª ÁַΠIgMÀÌ´Ù. ¼Ò¾Æ·ù¸¶Æ¼½º°üÀý¿°(juvenile rheumatoid arthritis: ¼Ò¾Æ±â¿¡ ¹ß»ýÇϴ ·ù¸¶Æ¼½º°üÀý¿°)À» ºñ·ÔÇÑ, ´Ù¸¥ °áÇÕÁ¶Á÷º´À̳ª °¨¿°º´¿¡µµ ³ªÅ¸³¯ ¼ö ÀÖ´Ù
¿µ¹® growth factor ÇÑ±Û ¼ºÀåÀÎÀÚ
¼³¸í   
  ¼¼Æ÷ÀÇ ºÐÈ­ ¹× ¼ºÀå¿¡ °ü¿©Çϴ ´Ü¹éÁú. ¼ºÀåÀÎÀڴ Á¤»ó ¼¼Æ÷Áֱ⿡ ÇʼöÀûÀ̱⠶§¹®¿¡ µ¿¹°ÀÇ »ý¸í¿¡ Áß´ëÇÑ ¿ä¼Ò°¡ µÈ´Ù. ¹«¾ùº¸´Ùµµ ¼ºÀåÀÎÀڴ Å¾ÆÀÇ ¹ßÀ°À» Á¶Á¤Çϰí Á¶Á÷ÀÇ À¯Áö ¹× º¸¼ö¿¡ Áß´ëÇÑ ¿ªÇÒÀ» Çϸç, Ç÷±¸ÀÇ »ý¼ºÀ» ÀÚ±ØÇÑ´Ù. ¶ÇÇÑ ¾ÏÀÇ ÁøÇà°úÁ¤¿¡µµ °ü¿©ÇÑ´Ù.
¿µ¹® risk factor ÇÑ±Û À§ÇèÀÎÀÚ
¼³¸í   
  ±¹Á¦¹æ»ç¼±¹æÈ£À§¿øÈ¸(ICRP)°¡ 1977³â ±Ç°í¿¡¼­ ¹æ»ç¼±¹æÈ£ÀÇ ¸ñÀûÀ¸·Î Ã¤ÅÃÇÑ Áö¼ö·Î, ´ÜÀ§¼±·®(1 Sv)´ç È®·üÀû ¿µÇâÀÇ ¹ß»ýÈ®·üÀ» ÃßÁ¤ÇÏ¿© ³ªÅ¸³½ °ÍÀÌ´Ù. »ý½Ä¼± ¼±·®¿¡ ´ëÇÑ À¯ÀüÀû¿µÇâÀÇ ¹ß»ý·ü(4¡¿10£­3/Sv)À̳ª Àû»ö°ñ¼ö¼±·®¿¡ ´ëÇÑ ¹éÇ÷º´ ¹ß»ý·ü(2¡¿10£­3/Sv)µî ¿Ü¿¡ »À, ÇãÆÄ, °©»ó»ù, Á¥»ù, ±âŸ Á¶Á÷ÀÇ À§ÇèÁö¼ö¸¦ ÃøÁ¤ÇÏ¿©, È®·üÀû ¿µÇâÀÇ Àü½Å¿¡ À־ Ä¡»çÀ§ÇèÁö¼öÀÇ Çհ踦 16.5¡¿10£­3/Sv·Î ÇÏ¿´´Ù. ±×ÈÄ ICRP´Â 1990³â ±Ç°í¿¡¼­ ´ë»óÀÌ µÇ´Â Á¶Á÷°ú Àå±â¸¦ Ãß°¡Çϰí, ¼öÄ¡ °³Á¤À» Çϸ鼭 ¸íεµ °¢¸ñÀûÈ®·üÁö¼ö¶ó°íÇÏ¿´´Ù. ÀÌ ±Ç°í¿¡ ÀÇÇϸé, Ä¡»çÀû È®·üÀû ¿µÇâÀÇ È®·üÁö¼öÀÇ ÇÕ°è´Â, ÀϹÝÀο¡ ÀÖ¾î 60.0¡¿10£­3/SvÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • leukocyte inhibitory factor
    ¹éÇ÷±¸¾ïÁ¦ÀÎÀÚ
  • luteotrophic hormone inhibitory factor
    Ȳ(»ö)üÀÚ±ØÈ£¸£¸ó¾ïÁ¦ÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • macrophage migration inhibitory factor
    Å«Æ÷½Ä¼¼Æ÷À̵¿ÀúÁöÀÎÀÚ, ´ë½Ä¼¼Æ÷À̵¿ÀúÁöÀÎÀÚ
  • prolactin inhibitory factor
    ÇÁ·Î¶ôƾºÐºñ¾ïÁ¦ÀÎÀÚ
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º¾ïÁ¦ÀÎÀÚ
  • gastric inhibitory polypeptide
    À§¾ïÁ¦Æú¸®ÆéƼµå
  • hypothalamic inhibitory hormone
    ½Ã»óÇϺξïÁ¦È£¸£¸ó
  • inhibitory action
    ¾ïÁ¦ÀÛ¿ë, ÀúÁöÀÛ¿ë
  • inhibitory enzyme
    ¾ïÁ¦È¿¼Ò
  • inhibitory hormone
    ¾ïÁ¦È£¸£¸ó
  • inhibitory interneuron
    ¾ïÁ¦»çÀ̽Ű漼Æ÷, ¾ïÁ¦°³Àç´º·±
  • inhibitory postsynaptic potential
    ¾ïÁ¦½Ã³ÀÀÌÈÄÀüÀ§, ¾ïÁ¦¿¬Á¢ÀÌÈÄÀüÀ§
  • inhibitory synapse
    ¾ïÁ¦½Ã³À½º, ¾ïÁ¦¿¬Á¢
  • inhibitory transmitter
    ¾ïÁ¦Àü´Þ¹°Áú
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • leukemia cutis
    ÇǺιéÇ÷º´
  • leukemia
    ¹éÇ÷º´
  • inhibitory action
    ¾ïÁ¦ÀÛ¿ë, ÀúÁöÀÛ¿ë
  • inhibitory enzyme
    ¾ïÁ¦È¿¼Ò
  • inhibitory effect
    ¾ïÁ¦È¿°ú
  • inhibitory hormone
    ¾ïÁ¦È£¸£¸ó
  • factor
    ÀÎÀÚ, ¿äÀÎ, °è¼ö
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • antiplatelet factor
    Ç×Ç÷¼ÒÆÇÀÎÀÚ
  • coagulation V factor
    Á¦5Ç÷¾×ÀÀ°íÀÎÀÚ
  • exclusion of confounding factor
    ±³¶õº¯¼ö¹èÁ¦
  • growth factor
    ¼ºÀåÀÎÀÚ
  • intrinsic factor
    ³»ÀÎÀÎÀÚ, ³»ÀÎÀÚ
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • leukocyte inhibitory factor
    ¹éÇ÷±¸¾ïÁ¦ÀÎÀÚ
  • luteotrophic hormone inhibitory factor
    ȲüÀÚ±ØÈ£¸£¸ó¾ïÁ¦ÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • macrophage migration inhibitory factor
    Å«Æ÷½Ä¼¼Æ÷À̵¿ÀúÁöÀÎÀÚ
  • prolactin inhibitory factor
    ÇÁ·Î¶ôƾºÐºñ¾ïÁ¦ÀÎÀÚ
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º¾ïÁ¦ÀÎÀÚ
  • inhibitory action
    ¾ïÁ¦ÀÛ¿ë, ÀúÁöÀÛ¿ë
  • reticular inhibitory area
    ±×¹°Ã¼¾ïÁ¦ºÎÀ§
  • central inhibitory state
    ÁßÃß¾ïÁ¦»óÅÂ
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ, ÃÖÀúÀúÁö³óµµ
  • inhibitory effect
    ¾ïÁ¦È¿°ú
  • inhibitory enzyme
    ¾ïÁ¦È¿¼Ò
  • peripheral inhibitory field
    ¸»ÃʾïÁ¦¿µ¿ª
  • hypothalamic inhibitory hormone
    ½Ã»óÇϺξïÁ¦È£¸£¸ó
  • inhibitory hormone
    ¾ïÁ¦È£¸£¸ó
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • prolactin-inhibitory factor(PIF)
    ÇÁ·Î¶ôƾ ºÐºñ ¾ïÁ¦ ÀÎÀÚ
  • F factor (fertility factor)
    FÀÎÀÚ, ¼öÅÂÀÎÀÚ
  • GIP (Gastric inhibitory peptide)
    À§Àå¾ïÁ¦(êÖíóåäð¤) ÆéŸÀ̵å
  • Gastric inhibitory peptide
    À§¾ïÁ¦(êÖåäð¤)È£¸£¸ó
  • Hypothalamic inhibitory hormones
    ½Ã»óÇϺξïÁ¦È£¸£¸ó
  • IPSP = inhibitory postsynaptic potential
    ¾ïÁ¦¼º(åäð¤àõ)½Ã³À½ºÈÄ(ý­)Àü¾Ð(ï³äâ)
  • inhibitory action
    ÀúÁöÀÛ¿ë(îÁò­íÂéÄ).
  • inhibitory autacoid
    ¾ïÁ¦¿À¿ÀŸÄÚÀ̵å.
  • inhibitory concentration, minimum (MIC)
    ¾ïÁ¦ÃÖ¼Ò³óµµ
  • inhibitory effect
    ¾ïÁ¦È¿°ú(åäð¤ Íý).
  • inhibitory effect
    ¾ïÁ¦È¿°ú.
  • inhibitory enzyme
    ÀúÇØÈ¿¼Ò.
  • inhibitory hormone
    ¾ïÁ¦(åäð¤)È£¸£¸ó.
  • inhibitory junctional potential
    ¾ïÁ¦¼º Á¢ÇÕºÎÀü¾Ð(ïÈùêݬï³äâ).
  • inhibitory nerve
    ¾ïÁ¦½Å°æ(åäð¤ãêÌè).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • luteotrop(h)ic hormone inhibitory factor =LTHIF
    ȲüÀÚ±ØÈ£¸£¸ó¾ïÁ¦ÀÎÀÚ(üÜô÷ô§Ð½¡­åäð¤ì×í­).
  • lymphocyte inhibitory factor (LIF)
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • macrophage migration inhibitory factor
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ.
  • migration inhibitory factor =MIF
    ´ë½Ä¼¼Æ÷À¯ÁÖÀúÁöÀÎÀÚ(ÓÞãÝá¬øàë´ñËîÁ ò­ì×í­).
  • migratory inhibitory factor
    À̵¿¼º ¾ïÁ¦ÀÎÀÚ
  • prolactin-inhibitory factor(PIF)
    ÇÁ·Î¶ôƾ ºÐºñ ¾ïÁ¦ ÀÎÀÚ
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º¾ïÁ¦ÀÎÀÚ (¡­åäð¤ì×í­).
  • leukemia cutis<³ª> leukemia of the skin
    ÇǺÎ(ù«Ý±)¹éÇ÷º´
  • central inhibitory state
    ÁßÃß¾ïÁ¦»óÅÂ.
  • central inhibitory state
    ÁßÃß¼º ¾ïÁ¦»óÅÂ
  • inhibitory action
    ÀúÁöÀÛ¿ë(îÁò­íÂéÄ).
  • inhibitory autacoid
    ¾ïÁ¦¿À¿ÀŸÄÚÀ̵å.
  • inhibitory concentration, minimum (MIC)
    ¾ïÁ¦ÃÖ¼Ò³óµµ
  • inhibitory effect
    ¾ïÁ¦È¿°ú.
  • inhibitory effect
    ¾ïÁ¦È¿°ú(åäð¤ Íý).
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Duffy factor
    ´õÇÇÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • leukemia
    ¹éÇ÷º´(ÛÜúìÜ»)
  • leukocyte inhibitory factor
    ¹éÇ÷±¸ÀúÇØÀÎÀÚ(ÛÜúìϹîÁúªì×í­)
  • gastric inhibitory peptide
    À§(êÖ) ÀúÇØ(îÁúª) ÆéŸÀ̵å
  • inhibitory autacoid
    ÀúÇØ(îÁúª)¿ÀŸÄÚÀ̵å
  • inhibitory medium
    "ÀúÇØ ¹è¾ç¾×(îÁúªÛÆå×äû), ÀúÇØ ¹èÁö(îÁúªÛÆò¢)"
  • inhibitory transmitter
    ÀúÇØ Àü´Þ¹°Áú(îÁúªîîÓ¹Úªòõ)
  • translationl inhibitory protein
    ¹ø¿ª ÀúÇØ ´Ü¹éÁú(Ûèæ»îÁúªÓ±ÛÜòõ)
  • acetate-replacing factor
    ¾Æ¼¼Æ®»ê(ß«)ġȯ ÀÎÀÚ(öÇüµì×í­)
  • achromotrichia factor
    ¸ð¹ß»ö¼Ò°áÇÌÀÎÀÚ (Ù¾Û¥ßäáÈÌÀù¹ì×í­)
  • angiogenic factor
    Ç÷°üÇü¼ºÀÎÀÚ(úìηû¡à÷ì×í­)
  • animal protein factor
    µ¿¹°´Ü¹éÁúÀÎÀÚ(ÔÑÚªÓ±ÛÜòõì×í­)
  • anti-egg-white injury factor
    Ç׳­¹é ¼Õ»óÀÎÀÚ(ù÷ÑëÛÜáßß¿ì×í­)
  • anti-fatty-liver-factor
    Ç×Áö¹æ°£ÀÎÀÚ(ù÷ò·Û¸ÊÜì×í­)
  • anti-gray-hair factor
    Ç×¹é¸ð¹ß ÀÎÀÚ(ù÷ÛÜÙ¾Û¥ì×í­)
  • antiacrodynia factor
    Ç×Áö´Üµ¿Åë ÀÎÀÚ(ù÷ò¶Ó®ÔÙ÷Ôì×í­)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • aleukemic leukemia
    ¹«¹éÇ÷º´¼º¹éÇ÷º´
  • leukemia
    ¹éÇ÷º´
  • lymphocytic leukemia
    ¸²ÇÁ±¸¼º¹éÇ÷º´
  • attenuation factor
    °¨¾à¿ä¼Ò, °¨¼è¿äÀÎ
  • conversion factor
    º¯È¯ÀÎÀÚ
  • factor
    ÀÎÀÚ
  • predisposing factor
    ¼ÒÀÎ, Áúº´¼ÒÁú
  • Q factor
    Å¥ÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½º¾çÀÎÀÚ
  • risk factor
    À§Çè¿äÀÎ
  • turbo factor
    Åͺ¸ÀÎÀÚ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AML Acute Myelogenous Leukemia
  Morphologic Classification(FABºÐ·ù)
   &n...
CF calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ...
LIF laser-induced fluorescence; left iliac fossa; left index finger; leukemia-inhibiting factor; leukocy...
MIF macrophage inhibitory factor; melanocyte[-stimulating hormone]-inhibiting factor; maximum inspirator...
AML acute monocytic leukemia; acute mucosal lesion; acute myeloblastic leukemia; acute myelocytic leukem...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LIFR leukemia inhibitory factor receptor
GIF Growth inhibitory factor
hLIF Human leukaemia inhibitory factor
LIF Leucocyte Inhibitory Factor
LIF Leucocyte migration inhibitory factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • effector-inhibitory factor
    È¿°ú±â ¾ïÁ¦ ÀÎÀÚ
  • macrophage migration inhibitory factor
    ´ë½Ä ¼¼Æ÷ À¯ÁÖ ÀúÁö ÀÎÀÚ, °Å½Ä ¼¼Æ÷ À¯ÁÖ ¾ïÁ¦ ÀÎÀÚ
  • migration inhibitory factor test
    À¯ÁÖ ÀúÁö ÀÎÀÚ ½ÃÇè
    ƯÀÌ Ç׿ø¿¡ ¹ÝÀÀÇÏ¿© ¸²ÇÁ±¸°¡ MIF¸¦ »ý¼ºÇÏ´Â µ¥ ´ëÇÑ »ýüÀÇ ½ÃÇè¹ýÀ¸·Î ¼¼Æ÷ ¸Å°³ ¸é¿ªÀ» Æò°¡ÇÏ´Â µ¥ »ç¿ëÇÑ´Ù. ÀϺΠ¸é¿ª °áÇÌ Áúº´, Áï DiGeorge ÁõÈıº, Wiskott-Aldrich ÁõÈıº, Hodgkin º´¿¡¼­´Â MIF°¡ »ý¼ºµÇÁö ¾Ê´Â´Ù.
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º ¾ïÁ¦ ÀÎÀÚ
  • IGF-I : insulin like growth factor-IÀÇ ¾àÀÚ. ¼ºÀåÆÇÀÎ epiphyseal plate¿¡ ¿¬°ñ »ý¼ºÀ» Áõ°¡½ÃÄÑ »ÀÀÇ ¼ºÀåÀ» ÃËÁøÇÑ´Ù.

    IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡

    Àν¶¸°¾ç ¼ºÀå ÀÎÀÚ °áÇÕ ´Ü¹éÁú
    insulinelike growth factor binding
  • single-factor versus multiple-factor analysis
    ´ÜÀÏ ¿ä¼Ò ºÐ¼® ´ë º¹ÇÕ ¿ä¼Ò ºÐ¼®
  • acute leukemia
    ±Þ¼º ¹éÇ÷º´
    ¿ø¹ßÇÏ´Â Á¶Ç÷ Á¶Á÷À̳ª ¹éÇ÷º´ ¼¼Æ÷ÀÇ Á¾·ù¿¡ µû¶ó °ñ¼ö¼º, ¸²ÇÁ¼º, ´Ü±¸¼ºÀ¸·Î ³ª´µ¾îÁö°í Ư¼öÇÑ °ÍÀ¸·Î¼­ Àû¹éÇ÷º´, ÇüÁú ¼¼Æ÷¼º ¹éÇ÷º´, È£»ê±¸¼º ¶Ç´Â È£¿°±â¼º ¹éÇ÷º´ µîÀÌ ÀÖ´Ù.
  • acute lymphoblastic leukemia
    ±Þ¼º ¸²ÇÁ¼º ¹éÇ÷º´
    1. À¯¾Æ ¹× ÀþÀº ¼ºÀο¡ È£¹ßÇÏ´Â Áúȯ. À¯¾Æ ±Þ¼º ¹éÇ÷º´ÀÇ »ó´ç¼ö¸¦ Â÷ÁöÇÑ´Ù. À¯¾Æ¿¡¼­ÀÇ È£¹ß ¿¬·ÉÀº 4¼¼ ÀüÈÄ. ÃÖ±Ù È­Çпä¹ýÀ¸·Î º´¿¡ °É¸° À¯¾ÆÀÇ 90%°¡ ¿ÏÀü Ä¡À¯µÈ´Ù. ¿¹ÈÄ´Â ¿¬·É, ¸é¿ªÇ¥ÇöÇü ±×¸®°í ¼¼Æ÷ À¯ÀüÇÐÀûÀÎ º¯È­¿¡ ÀÇÇØ ¿µÇâÀ» ¹Þ´Â´Ù. 2. ȯÀÚÀÇ 90%°¡ ¹éÇ÷±¸ ¼¼Æ÷¿¡¼­ ÇÙÇü ÀÌ»óÀ» º¸ÀδÙ. ÀϺΠ¼¼Æ÷À¯Àü º¯È­°¡ ¼ºº°, ¿¬·É, ¸é¿ªÇ¥ÇöÇü °°Àº º¯ÀÌ¿ä¼Ò¿Í »ó°ü¾øÀÌ ¿¹ÈÄ¿¡ ´ëÇÑ Á¤º¸¸¦ ÁØ´Ù. 51-60 ¿°»öü »çÀÌÀÇ °í¹è¼ö¼ºÀÌ ¿¹Èİ¡ ÁÁÀº °ÍÀº ÀÌ¹Ì Àß ¾Ë·ÁÁ® ÀÖ´Ù.
  • acute megakaryocytic leukemia
    ±Þ¼º °ÅÇÙ±¸¼º ¹éÇ÷º´
  • acute mixed-lineage leukmia£¨±Þ¼º È¥ÇÕ-Á÷°è¼º ¹éÇ÷º´£©

    acute monocytic leukemia

    ±Þ¼º ´Ü±¸ ¹éÇ÷º´, ±Þ¼º ´Ü±¸¼º ¹éÇ÷º´
    ±Þ¼º ¹éÇ÷º´ÀÇ ÀÏÁ¾À̰í À¯¾à´Ü±¸°¡ ¹éÇ÷º´È­ÇÑ °ÍÀÌ´Ù. °ñ¼ö¿¡¼­ °ú¸³±¸°èÀÇ À¯¾à¼¼Æ÷¿Í ´Ü±¸°èÀÇ À¯¾à¼¼Æ÷°¡ È¥ÀçÇÏ´Â ¼ö°¡ ÀÖ°í ÀÌ °æ¿ì¿¡´Â ±Þ¼º °ñ¼ö´Ü±¸¼º ¹éÇ÷º´À̶ó°í ÇÑ´Ù.
  • acute myelocytic leukemia
    ±Þ¼º °ñ¼ö±¸¼º ¹éÇ÷º´
    ±Þ¼ºÀ¸·Î ¹ßº´ ÁøÇàµÇ´Â °ñ¼ö¼¼Æ÷ ±â¿øÀÇ ¹éÇ÷º´À¸·Î º¸Åë ¿­°ú ÇÔ²² ÀϾ´Ù.
  • acute myelomonoblastic leukemia
    ±Þ¼º °ñ¼ö ´Ü±¸¼º ¹éÇ÷º´
  • adult T cell leukemia
    ¼ºÀÎ T¼¼Æ÷ ¹éÇ÷º´
    ¹ßÁõ ¿¬·ÉÀº Æò±Õ 51¼¼, ÀϺ» Kyushu, Shikoku, Kii ¹Ýµµ Áö¹æ¿¡¼­ ´Ù¹ßÇϰí ÇǺΠħÀ± ¹× °£Àå, ºñÀå, ¸²ÇÁÀý Á¾´ë¸¦ ÈçÈ÷ º¼ ¼ö Àִµ¥ ºóÇ÷Àº ¾ø´ø°¡, À־ °æµµ, °ñ¼ö¿¡ÀÇ Ä§À±Àº º¸Åë ÇöÀúÇÏÁö ¾Ê´Ù. 50% »ýÁ¸Àº 4.4°³¿ù·Î ª´Ù. ¹éÇ÷º´ ¼¼Æ÷ÀÇ Æ¯Â¡Àº ÇÙÀÌ ÀÌÇüÀÌ¸ç ºÐ¿±»ó, È­ÆÇ»ó µîÀ¸·Î Áø´Ü¿¡ »ç¿ëµÈ´Ù.
  • aleukemic leukemia
    ¹«¹éÇ÷º´¼º ¹éÇ÷º´
  • chronic granulocytic leukemia
    ¸¸¼º °ú¸³±¸ ¹éÇ÷º´, ¸¸¼º °ú¸³±¸¼º ¹éÇ÷º´
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
leukemia <haematology> An acute or chronic disease of unknown cause in man and other warm blooded animals that involves the blood forming organs, is characterised by an abnormal increase in the number of leucocytes in the tissues of the body with or without a corresponding increase of those in the circulating blood and is classified according of the type leucocyte most prominently involved.
(18 Nov 1997)
migration-inhibitory factor <growth factor> A soluble, nondialysable factor that is produced by sensitised lymphocytes following exposure to a specific antigen. It inhibits macrophage migration and causes adherence.
It was originally defined on the basis of inhibition of emigration of mononuclear cells from capillary (haematocrit) tubes, more recently a 13 kD protein with migration inhibitory activity has been isolated.
Acronym: MIF
Synonym: inhibition factor.
(22 Sep 2002)
migration-inhibitory factor test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
Leukaemia inhibitory factor <growth factor> Polypeptide growth factor or cytokine with wide range of activities. Regulates growth and differentiation of primordial germ cells and embryonic stem cells but has effects on peripheral neurons, osteoblasts, adipocytes and various cells of the myeloid lineage. Given to adult animals induces weight loss, behavioural disorders and bone abnormalities. Many of the effects of LIF in vitro can be mimicked by IL-6, oncostatin M and ciliary neurotrophic factor, all of which interact indirectly with gp130, a shared tranducer subunit.
(18 Nov 1997)
macrophage migration-inhibitory factors Proteins released by sensitised lymphocytes and possibly other cells that inhibit the migration of macrophages away from the release site. The structure and chemical properties may vary with the species and type of releasing cell.
(12 Dec 1998)
gastric inhibitory polypeptide <hormone> Peptide hormone (43 amino acids) that stimulates insulin release and inhibits the release of gastric acid and pepsin.
Acronym: GIP
(18 Nov 1997)
G-protein, inhibitory GI A g-protein that inhibits adenylyl cyclase and activates k+ channels.
(12 Dec 1998)
minimal inhibitory concentration <microbiology, pharmacology> The lowest concentration of antibiotic sufficient to inhibit bacterial growth when tested in vitro.
(05 Mar 2000)
inhibitory Of or pertaining to, or producing, inhibition; consisting in inhibition; tending or serving to inhibit; as, the inhibitory action of the pneumogastric on the respiratory center. "I would not have you consider these criticisms as inhibitory.
<physiology> " (Lamb) Inhibitory nerves, those nerves which modify, inhibit, or suppress a motor or secretory act already in progress.
Origin: LL. Inhibitorius: cf. F. Inhibitoire.
Source: Websters Dictionary
(01 Mar 1998)
inhibitory fibres Nerve fibre's that inhibit the activity of the nerve cells with which they have synaptic connections, or of the effector tissue (smooth muscle, heart muscle, glands) in which they terminate.
(05 Mar 2000)
inhibitory junction potential Hyperpolarization of smooth muscle produced by stimulation of inhibitory nerves.
(05 Mar 2000)
inhibitory-motor <physiology> A term applied to certain nerve centers which govern or restrain subsidiary centers, from which motor impressions issue.
Source: Websters Dictionary
(01 Mar 1998)
inhibitory nerve <anatomy, nerve> A nerve conveying impulses that diminish functional activity in a part.
(05 Mar 2000)
inhibitory postsynaptic potential The change in potential produced in the membrane of the next neuron when an impulse which has an inhibitory influence arrives at the synapse; it is a local change in the direction of hyperpolarization; the frequency of discharge of a given neuron is determined by the extent to which impulses that lead to excitatory postsynaptic potential's predominate over those that cause inhibitory postsynaptic potential's.
(05 Mar 2000)
inhibitory synapse A synapse in which an action potential in the presynaptic cell reduces the probability of an action potential occurring in the postsynaptic cell. The most common inhibitory neurotransmitter is GABA, this opens channels in the postsynaptic cell which tend to stabilise its resting potential, thus rendering it less likely to fire.
See: excitatory synapse, presynaptic inhibition, postsynaptic inhibition.
(18 Nov 1997)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 2 ÆäÀÌÁö: 1
  • Leukemia Inhibitory Factor - »õâ An INTERLEUKIN-6 related cytokine that exhibits pleiotrophic effects on many physiological systems that involve cell proliferation, differentiation, and survival. Leukemia inhibitory factor binds to and acts through the LIF RECEPTOR.
    Synonyms : AM424, AMRAD Brand of Recombinant Human Leukemia Inhibitory Factor, Cholinergic Differentiation Factor, D Factor (Leukemia Inhibitory Factor), Differentiation-Stimulating Factor, Emfilermin, Myeloid Differentiation-Stimulating Factor
  • Leukemia Inhibitory Factor Receptor alpha Subunit - »õâ A receptor subunit that combines with CYTOKINE RECEPTOR GP130 to form the dual specificity receptor for LEUKEMIA INHIBITORY FACTOR and ONCOSTATIN M. The subunit is also a component of the CILIARY NEUROTROPHIC FACTOR RECEPTOR. Both membrane-bound and secreted isoforms of the receptor subunit exist due to ALTERNATIVE SPLICING of its mRNA. The secreted isoform is believed to act as an inhibitory receptor, while the membrane-bound form is a signaling receptor.
    Synonyms : CD118 Antigen, LIF Receptor alpha Subunit, Antigen, CD118
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
leukemia inhibitory factor (LIF) A signalling molecule originally discovered in association with leukemia, but now known to have many functions, including the support of pregnancy by the endometrium as it forms decidua.
Ãâó: www.jansen.com.au/Dictionary_JL.html
leukemia inhibitory factor A cell messenger protein originally noted for inhibition of mouse M1 myeloid leukemia cells that also has effects including inhibiting differentiation to maintain stem cells.
Ãâó: www.bioethics.gov/reports/stemcell/glossary.html
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inhibitory
    ±ÝÁöÀÇ
  • inhibitory
    ±ÝÁöÀÇ;Á¦Áö(¾ïÁ¦)ÇÏ´Â
  • leukemia
    ¹éÇ÷º´
  • leukemia
    ¹éÇ÷º´
  • leukemia
    ¹èÇ÷(±¸ °ú´Ù)Áõ !
  • factor
    ¿ä¼Ò,¿äÀÎ
  • F factor
    FÀÎÀÚ;¿°¼ºÀÎÀÚ
  • R factor
    R ÀÎÀÚ(¼¼±ÕÀÇ ¾àÁ¦ ³»¼º ÀÎÀÚ)
  • Rh factor
    ¸®¼­½º ÀÎÀÚ(ÀûÇ÷±¸ ¼Ó¿¡ ÀÖ´Â ÀÀÇ÷¼Ò)
  • Rhesus factor(antigen)
    =RH FACTOR
  • coal-factor
    ¼®Åº Áß°³ »óÀÎ(µµ¸Å »óÀÎ)
  • common factor
    =COMMON DIVISOR
  • conversion factor
    (¹®ÀÇ.ÀÚ·áû±¸¿¡¼­ ½ÇÁ¦ »óǰ±¸¸ÅÀÎÀ¸·ÎÀÇ)ÀüȯÀ²
  • factor
    ¿ä¼Ò;¿äÀÎ;¿øÀÎ;Àμö;ÀÎÀÚ;°è¼ö;À²;´ë¸®»ó;µµ¸Å»ó;Á߸ÅÀÎ
  • factor analysis
    ÀÎÀÚ ºÐ¼®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á